MMRGlobal, Inc. (fka MMRF)

[tbone1360]

An update on MMRGlobal biotech licensing matters.

There have been numerous comments directed to MMR in response to a recent article in Drugs.com.

Accordingly MMR has the following comment. MMR remains engaged in licensing portions of its biotechnology portfolio with a major biopharmaceutical company. The details of that non-exclusive license agreement can be found in MMR’s 8K on file at
... http://www.sec.gov/Archives/edgar/data/1285701/000113626110000355/body8k.htm . To date MMR has reported receiving in excess of $900,000 related to this agreement. To the best of the Company’s knowledge the article has no adverse bearing on MMR’s licensing agreement.

MMR’s biotechnology portfolio includes assets such as anti-CD20 monoclonal antibodies, data from vaccine trials, thousands of patient tumor samples and other intellectual property. The Company acquired its biotechnology portfolio as a result of a reverse merger with Favrille, Inc., a biopharmaceutical company, in January 2009. The portfolio includes but is not limited to research and development on the FavId™/Specifid™ vaccine trials and use of customized tumor cells to treat lymphoma patients and other technologies. Today the Company continues to protect these assets through its extensive biotechnology patent portfolio.

http://www.sec.gov/Archives/edgar/data/1285701/000113626110000355/body8k.htm